Literature DB >> 20664975

Endothelial cell-expressed Tim-3 facilitates metastasis of melanoma cells by activating the NF-kappaB pathway.

Feng-Hua Wu1, Ye Yuan, Dong Li, Zhang Lei, Chuan-Wang Song, Yan-Yan Liu, Bo Li, Bo Huang, Zuo-Hua Feng, Gui-Mei Zhang.   

Abstract

T cell immunoglobulin and mucin domain-3 (Tim-3) is originally recognized as a receptor of Th1 cells. We found that Tim-3 could be expressed in endothelial cells after stimulation with tumor cell-released TLR4 ligand. Tim-3 expressed by endothelial cells does not function as the receptor of galectin-9, but mediates the interaction of endothelial cells with tumor cells. The engagement of endothelial cell-expressed Tim-3 with a non-galectin 9 putative receptor on B16 melanoma cells could trigger the NF-kappaB signaling pathway in B16 cells. The activated NF-kappaB not only promoted the proliferation of B16 cells, but also enhanced apoptosis resistance of B16 cells by up-regulating Bcl-2 and Bcl-xL and down-regulating Bax. Consistently, Tim-3 facilitated the survival of B16 cells in the blood stream, arrested in the lung and following invasion, resulted in more metastatic nodules in the lung. These findings suggest that endothelial cell-expressed Tim-3 increases tumor cell metastatic potential by facilitating tumor cell intravasation, survival in blood stream and extravasation. Thus, anti-inflammation or blockade of Tim-3 may contribute to the prevention of metastasis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20664975

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  13 in total

1.  T cell immunoglobulin- and mucin-domain-containing molecule 3 gene polymorphisms and susceptibility to pancreatic cancer.

Authors:  Danian Tong; Yujia Zhou; Wei Chen; Yang Deng; Lei Li; Zhenyi Jia; Dachuan Qi
Journal:  Mol Biol Rep       Date:  2012-06-26       Impact factor: 2.316

Review 2.  Emerging Tim-3 functions in antimicrobial and tumor immunity.

Authors:  Kaori Sakuishi; Pushpa Jayaraman; Samuel M Behar; Ana C Anderson; Vijay K Kuchroo
Journal:  Trends Immunol       Date:  2011-06-21       Impact factor: 16.687

Review 3.  Immunobiology of high-grade serous ovarian cancer: lessons for clinical translation.

Authors:  Lana E Kandalaft; Denarda Dangaj Laniti; George Coukos
Journal:  Nat Rev Cancer       Date:  2022-09-15       Impact factor: 69.800

4.  NF-κB Inhibition Suppresses Experimental Melanoma Lung Metastasis.

Authors:  Tomoko Stansel; Samuel A Wickline; Hua Pan
Journal:  J Cancer Sci Clin Ther       Date:  2020-08-14

5.  Antitumorigenic effect of damnacanthal on melanoma cell viability through p53 and NF-κB/caspase-3 signaling pathways.

Authors:  Xin Zhang; Ping Fang; Zigang Zhao; Xiangyu Ding; Fang Xie; Yilin Wang; Chengxin Li
Journal:  Oncol Lett       Date:  2018-09-03       Impact factor: 2.967

6.  Effects of Tim-3 silencing on the viability of fibroblast-like synoviocytes and lipopolysaccharide-induced inflammatory reactions.

Authors:  Rui Wu; Li Long; Qiqi Chen; Xiaodan Wu; Jing Zhu; Bin Zhou; Jia Cheng
Journal:  Exp Ther Med       Date:  2017-07-19       Impact factor: 2.447

Review 7.  Tim-3: an activation marker and activation limiter of innate immune cells.

Authors:  Gencheng Han; Guojiang Chen; Beifen Shen; Yan Li
Journal:  Front Immunol       Date:  2013-12-10       Impact factor: 7.561

8.  Ellagic acid inhibits melanoma growth in vitro.

Authors:  J Daniel Jensen; Jeffrey H Dunn; Yuchun Luo; Weimin Liu; Mayumi Fujita; Robert P Dellavalle
Journal:  Dermatol Reports       Date:  2011-12-12

9.  Tim-3 inhibits macrophage control of Listeria monocytogenes by inhibiting Nrf2.

Authors:  Zhiding Wang; Dejun Sun; Guojiang Chen; Ge Li; Shuaijie Dou; Renxi Wang; He Xiao; Chunmei Hou; Yan Li; Jiannan Feng; Beifen Shen; Gencheng Han
Journal:  Sci Rep       Date:  2017-02-16       Impact factor: 4.379

Review 10.  The Common Costimulatory and Coinhibitory Signaling Molecules in Head and Neck Squamous Cell Carcinoma.

Authors:  Peng Liao; Haofan Wang; Ya-Ling Tang; Ya-Jie Tang; Xin-Hua Liang
Journal:  Front Immunol       Date:  2019-10-23       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.